Company Reports

Lilly presented data from multiple clinical programs as part of October's annual meeting of the European Association for the Study of Diabetes, including Phase 2 data for a combination of amylin agonist eloralintide and Lilly's blockbuster cardiometabolic drug tirzepatide (Mounjaro/Zepbound).

Lilly reported 48% second-quarter revenue growth and 33% non-GAAP EPS growth, which included acquisition charges. Management raised the midpoints of its 2026 guidance to $86 billion in revenue and $36 per share in non-GAAP EPS. Shares rose 5% on Aug. 5.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as it is launching several new blockbusters and patent losses are fading.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as it is launching several new blockbusters and patent losses are fading.

Eli Lilly reported 56% revenue growth and 156% non-GAAP EPS growth in the first quarter, and management raised full-year revenue guidance by $2 billion to a range of $82 billion-$85 billion, implying 28% growth at the midpoint. Shares rose 10% intraday on April 30.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as it is launching several new blockbusters and patent losses are fading.

Lilly announced an agreement to acquire Kelonia Therapeutics and its in vivo CAR-T pipeline and technology for $3.25 billion upfront and potential total payments up to $7 billion. The deal is expected to close in the second half of 2026. Lilly shares were flat in early trading April 20.

Eli Lilly received US Food and Drug Administration approval of Foundayo (orforglipron) on April 1 for patients with obesity/overweight, after an accelerated review using a national priority voucher. Shares rose 4% in intraday trading on the news.

Eli Lilly reported increases of 43% in revenue and 42% in non-GAAP earnings per share for the fourth quarter. For 2026, management guided for $81.5 billion in revenue (25% growth) and non-GAAP EPS of $34.25 (41% growth) at the midpoint. The shares were up 10% intraday on Feb. 4.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as it is launching several new blockbusters and patent losses are fading.

Novo Nordisk received Food and Drug Administration approval for its Wegovy pill as a treatment for obesity on Dec. 22. The company plans to launch the 25-milligram semaglutide pill in the US in early January. Novo shares were up roughly 9% in early Dec. 23 trading.

On Nov. 6, Novo and Lilly announced a deal with the Trump administration to lower obesity drug prices in several channels in exchange for expanded Medicare access and a tariff grace period. Both received national priority vouchers. Lilly also disclosed phase 2 data for amylin drug eloralintide.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as it is launching several new blockbusters and patent losses are fading.

Eli Lilly reported 54% revenue growth in the third quarter, as its diabetes and obesity drug tirzepatide (Mounjaro/Zepbound) continues to gain share globally, and management raised top- and bottom-line guidance. Shares rose nearly 4% on Oct. 30.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as the company is launching several new blockbusters and patent losses are fading.

On Sept. 25, President Donald Trump announced that 100% tariffs on branded or patented pharmaceuticals will be enacted starting Oct. 1, unless the drugmaker is building its manufacturing plant in the US. At the time of this writing, share prices for big drugmakers have held steady.

Lilly reported Aug. 26 that oral GLP-1 drug candidate orforglipron generated 8.3% placebo-adjusted weight loss at 72 weeks at the highest 36 mg dose among compliant patients with obesity or overweight and Type 2 diabetes in the Attain-2 study.

Lilly's 38% revenue growth and 61% non-GAAP EPS growth in the second quarter was above consensus expectations. Management raised 2025 guidance to ranges of $60 billion-$62 billion in revenue and $21.75-$23.00 in non-GAAP EPS. Lilly also announced Attain-1 obesity data for oral GLP-1 orforglipron.

In letters to pharma CEOs on July 31, President Donald Trump pushed firms to implement most-favored-nation pricing for Medicaid by the end of September. This follows a policy announced July 28 that will impose 15% tariffs on imports from the EU, replacing potential Section 232 investigation tariffs.

President Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services to lower US drug prices if no deal is reached.